

Laser Capture Microdissection (LCM) for the Analysis of Macrophage Gene Expression from Atherosclerotic Lesions



ABSTRACT

Macrophage foam cells are integral in the development of atherosclerotic lesions, however gene expression studies are complicated by the cellular heterogeneity of atherosclerotic plaque. This application note describes a protocol for LCM of cells identified immunohistochemically, followed by real-time RT-PCR to selectively analyze RNA from foam cells of apolipoprotein E-deficient mice. The specificity of the procedure and the measurement of gene induction in laser captured cell populations after an in vivo perturbation are illustrated. These techniques will facilitate the study of atherosclerosis.

INTRODUCTION

Macrophage foam cells are critical in the development of atherosclerosis (1-3). Therefore, a better understanding of the gene expression changes in foam cells during disease progression and regression has become an important goal in order to develop potential therapies and interventions (4-6).

However, the study of macrophage foam cell gene expression in arterial lesions is hampered by the cellular heterogeneity of arterial tissue, which, besides macrophages, also contains lymphocytes, smooth muscle cells, endothelial cells, and adventitial fibroblasts. To overcome these technical obstacles, we describe here a method for the use of LCM (7, 8) to selectively procure macrophage foam cells from arterial lesions (identified by the macrophage-specific marker, CD68/ Macrosialin (9, 10).

APPLICATION NOTE #1

RNA extracted from the laser captured foam cell material was used to quantify, by real-time quantitative RT-PCR, the fold of enrichment and to measure the induction of specific transcripts in response to an inflammatory stimulus. These methods make possible the quantitative analysis of gene expression in macrophage foam cells and add a powerful dimension to the study of atherosclerosis.

EQUIPMENT AND REAGENTS

This protocol requires the following reagents:

I. CRYOSECTIONING

- Isoflurane (Baxter, Cat. #Forane™)
- Phosphate Buffered Saline (PBS) (Fisher Scientific, Cat. #FLBP399-1)
- OCT cryoembedding medium (VWR, Cat. #25608-930)
- ColorFrost Plus™ slides (Fisher Scientific, Cat. #12-550-17)

II. IMMUNOHISTOCHEMISTRY

- Normal goat serum (Vector Laboratories, Cat. #S-1000)
- Anti-CD68/Macrosialin antibody (Serotec, Cat. #MCA1957S)
- SUPERaseIn™ (Ambion, Cat. #2694)

- Biotinylated rabbit-anti-rat IgG mouse-adsorbed secondary antibody (Vector Laboratories, Cat. #BA-4001)
- Vectastain ABC Alk Phosphatase Kit (Vector Laboratories, Cat. #AK-5200)
- Vector Red substrate (Vector Laboratories, Cat. #SK-5100)

III. LASER CAPTURE MICRODISSECTION

- Accuva Collect Laser Capture Microdissection instrument (Laxco, Inc., LCM-FL1A)
- CapSure® Macro LCM caps (ThermoFisher, Cat. #LCM0211)

IV. RNA EXTRACTION/ ISOLATION AND QUANTIFICATION

- PicoPure RNA Isolation Kit (ThermoFisher, Cat. # KIT0204)
- RNase-Free DNase Set (Qiagen, Cat. #79254)
- Ribogreen RNA quantification kit (Molecular Probes, Cat. #R11490)

V. REAL-TIME QUANTITATIVE RT-PCR

- Gene-specific TaqMan primers and probes (Biosearch Technologies, Cat. # (see Table I)
- SuperScript II reverse transcriptase enzyme (Invitrogen, Cat. #18064-014)
- 10mM dNTP mix (Invitrogen, Cat. #18427-013)
- Taq DNA polymerase (Invitrogen, Cat. #10342-020)
- RnaseOut RNase inhibitor (Invitrogen, Cat. #10777-019)
- Acetylated BSA (1µg/ml) (Promega, Cat. #R9646A)
- 50X 5-carboxy-X-rhodamine (ROX) internal reference dye (Invitrogen, Cat. #12223-012)

The following laboratory equipment is required to complete the protocol:

- Disposable gloves
- Dry ice
- Cryostat
- ABI Prism™ 7700 Sequence Detection System (Applied Biosystems)
- RNase AWAY (Fisher Scientific, Cat. #14-375-35)
- Nuclease-free pipette tips
- MicroAmp optical tubes (Applied Biosystems, Cat. #N801-0933)
- MicroAmp optical caps (Applied Biosystems, Cat. #N801-0935)
- Nusieve 3:1 agarose (BioWhittaker Molecular Applications)
- Immunostaining jars

RNASE-FREE TECHNIQUE

All reagents were maintained under RNase-free sterile conditions.

1. Wear disposable gloves and change them frequently.
2. Pipettmen are wiped with RNase AWAY® prior to use according to manufacturer's instructions.
3. Cryosections are temporarily stored in the cryostat and later into a -80°C freezer to prevent RNA degradation.
4. Use RNase-free solutions (water prepared by treatment with 0.2% DEPC overnight and autoclaved).
5. Concentration of antibodies and duration of incubations have been optimized so as to preserve the quality of RNA and to yield specific staining having a high signal/noise ratio.
6. Addition of SuperaseIn RNase Inhibitor to the antibody cocktails during immunostaining is recommended as it prevents RNA degradation during the incubation steps. (NOTE: Do not add the SuperaseIn to the ABC Alk-Phos enzymatic reaction as it will completely inhibit the staining).

SPECIAL CONSIDERATIONS

1. We have observed that addition of the Superscript RNase inhibitor to the alkaline phosphatase enzyme completely inhibits the reaction and does not produce any visible staining.
2. It is important that the alcohols and the xylenes be prepared fresh and not be reused since insufficient dehydration will dramatically affect the ability to perform successful LCM.
3. RNA extraction of the laser captured material yielded 3.5 ng from 30 6 μm thick sections, equivalent to volume of $1.35 \times 10^6 \mu\text{m}^3$ of CD68+ immunostaining).
4. To generate the standard curves for CD68 and α -actin, total RNA was prepared from thioglycol late-elicited intraperitoneal macrophages and cultured primary aortic smooth muscle cells.
5. The probe, labeled at the 5' and 3' ends with 6-carboxyfluorescein (6-FAM) reporter and tetra methyl-6-carboxy rhodamine (TAMRA) quencher, respectively, is hydrolyzed by the 5' exonuclease activity of Taq DNA polymerase, causing an increase in fluorescent signal that is measured in "real-time" after each cycle of PCR amplification. Standard curves were constructed by plotting \log_{10} RNA starting quantity vs. cycle threshold (Fig. 3A). On the basis of appropriate serially diluted standard RNA, the amount of input standard RNA yielding the same amount of PCR product measured from an unknown sample was calculated.

METHOD

A. Animals and Tissue Processing

1. Apolipoprotein E^{-/-} mice (Jackson Laboratories), a standard model of human atherosclerosis, are fed a standard chow diet for 20 weeks.
2. Sacrifice mice by exsanguination (under general anesthesia with isoflurane) by intra-vascular perfusion with phosphate buffered saline (PBS). The thorax is opened and a 21-gauge cannula inserted to the left ventricle.
3. Incise the right atrium to allow efflux of blood. Perfuse at physiological pressure (100mmHg) with PBS.
4. Remove heart and aorta en bloc. Transect the heart at the lower poles of the atria and perpendicular to them. This plane is parallel to that of the aortic valve.
5. Place the upper half on the heart (containing the atria) in an embedding mold filled with OCT cryoembedding medium, and allow it to infiltrate into the cavity of the heart.
6. Position the heart flat with the cut surface on the bottom of the embedding mold. Fill the embedding mold with OCT and freeze on dry ice.
7. Store specimens at -80°C .
8. Section tissue blocks at 6 μm thickness and mount on positively charged Color Frost Plus slides.

B. Immunodetection of CD68+ Macrophages for LCM.

Standard immunohistochemical staining protocols usually require prolonged incubation periods in aqueous media, which results in significant degradation of RNA. To overcome this limitation, a modified rapid immunostaining protocol was developed for macrophage-specific CD68/Macrosialin that does not significantly affect RNA yields (<12% reduction of total RNA in immunostained versus non-immunostained whole tissue sections) (11).

1. Allow frozen sections to air dry for 1 min and then fix in 70% ethanol for 15 sec followed by cold acetone for 5 min.
2. Incubate slides with anti-mouse CD68/macrosialin IgG (1:10 dilution) in 4% goat blocking serum (made in PBS) supplemented with Superscript RNase inhibitor (0.4U/ μ l) for 1 min at room temperature (RT).
3. Rinse slides in PBS 3 times for 5 min each.
4. Incubate slides with biotinylated rabbit-anti-rat IgG mouse-adsorbed secondary antibody (20 μ g/ml final) in 4% goat blocking serum supplemented with Superscript RNase inhibitor (0.4U/ μ l) for 1 min at RT.
5. Rinse slides in PBS 3 times for 5 min each. Incubate slides with Vectastain ABC Alk-Phos reagent (prepared at least 30 minutes in advance according to manufacturer's instructions) for 1 min. at RT (see Special Considerations, Note 1).
7. Rinse slides in 100mM Tris-HCl Buffer pH. 7.5 for 1 min. at RT.
8. Apply Vector Red chromogenic substrate until adequate intensity of staining develops (~5 - 10 min). Immerse slides in RNase-Free water to stop reaction.
9. Sections are counterstained with Harris modified hematoxylin for ~ 5 sec.
10. Sections are subsequently dehydrated in graded ethanols (95% 2X, 1 min each, 100% 3X, 3 min each) and cleared in xylene (3X, 2 min each). Allow slides to air dry under a vacuum hood for 30 min (see Special Considerations, Note 2).

C. LCM and RNA Extraction

Laser capture was performed under direct microscopic visualization on the CD68-positively stained areas by activating a thermoplastic film mounted on optically transparent LCM caps over selected regions. 30 proximal aortic sections from each apolipoprotein E-deficient mouse were microdissected in regions immunostained positive for CD68/Macrosialin and with morphologically-identifiable cells having the characteristic "foamy" appearance. Approximately 300 laser pulses were performed on each section.




Figure 1. LCM of macrophage foam cells from atherosclerotic lesions of apolipoprotein E^{-/-} mice. Selection of cells for laser capture was guided by immunohistochemical detection of macrophage specific marker CD68/Macrosialin (red staining). **A.** Proximal aortic lesion is shown prior LCM (200X; inset: 30X). **B.** Remaining tissue section after LCM. **C.** The homogeneity of the captured material is confirmed under microscopic visualization prior to processing for RNA extraction.

1. RNA was extracted/isolated using the PicoPure™ RNA Isolation Kit as per manufacturer's instructions.
 2. Examine the surface of the LCM cap under the microscope to ensure complete cell extraction.
 3. To eliminate potential genomic DNA contamination, RNA samples were treated with the DNase (Qiagen) directly onto the column as per manufacturer's instructions.
 4. RNA concentration was measured by a Ribogreen sensitive nucleic-acid dye binding assay according to manufacturer's instructions (see Special Considerations, Note 3).
 5. Store LCM RNA sample at -80°C . Total RNA may be used immediately or stored at -80°C until used.
3. To 5 μl of samples (100 pg) and appropriate standard RNA (10 ng - 1 pg serial dilutions), add separately 20 μl of the master mix (see Special Considerations, Note 4).
 4. Set the Sequence Detection System 7700 to the following cycling conditions: RT-PCR stage (95°C , 10 sec; 45°C , 50 min; 95°C , 2min) immediately followed by 40 cycles of PCR amplification (denaturation: 95°C , 15 sec; annealing/extension: 60°C , 1 min). The reaction products are separated on a 2% Nusieve 3:1 agarose gel (Fig. 3B) to verify the appropriate size of the amplicons (~63- 67 bp; see Special Considerations, Note 5).


D. Analysis of macrophage foam cell gene expression by real-time quantitative RT-PCR.

Real-time quantitative RT-PCR is a very sensitive method which allows for measurements of low abundance transcripts and, unlike Northern or RNase protection assays, requires only a very small amount of total RNA (typically 100 pg - 1ng). A comprehensive review of the methodology has been done by Bustin, 2000. RT-PCR and subsequent PCR are both carried out in a single sealed optical tube using gene specific primers and fluorogenic probes.

1. Prepare a master mix containing the following for each reaction: 1X first strand buffer (50mM Tris-HCl pH 8.3, 75mM KCl, 3mM MgCl₂), 5mM DTT, 0.3mM dNTP mix, 20U SuperScript II reverse transcriptase enzyme, 2.5U Taq DNA polymerase, 40U RnaseOut RNase inhibitor, 0.625 μg acetylated BSA, and 1X 5-carboxy-X-rhodamine internal reference dye (Invitrogen Life Technologies, Carlsbad, CA) in optical tubes.
2. Add 50nM of the forward primer and reverse primer, and 100nM of the probe to the master mix for each reaction.

RESULTS

To aid in the identification of foam cells for laser capture, aortic sections were immunostained for the CD68/Macrosialin antigen (red color; Fig. 1). RNA extraction of the laser captured material yielded 3.52 ± 0.18 ng of total RNA per animal (mean \pm SD). The integrity of the RNA was assessed and was found to be of high quality (Fig. 2). Peaks corresponding to the 28S and 18S ribosomal RNAs were clearly visible on the BioAnalyzerTM profile (A) and pseudo-electropherogram (B). There was no detectable genomic DNA contamination, as evidenced by a lack of additional peaks to the right of the 28S peak. Typically, RNase degradation of total RNA samples produces a shift in the RNA size distribution toward smaller fragments and a decrease in fluorescence signal and the 18S and 28S peak can no longer be identified with certainty. Degraded total RNA will lack a smooth baseline and typically contains multiple peaks that are as large as or larger than the ribosomal peaks. For the different gene transcripts measured, the quantitative RT-PCR assay was highly reproducible (median intra-assay coefficients of variation, based on >20 samples run in duplicate, ranged between 2.4% and 7.7%) and highly sensitive (10 pg of starting total RNA resulted in detectable product formation). In Fig. 3A, representative standard curve plots for CD68 (top) and α -actin (bottom) are shown. For all of the genes measured, a linear relationship between the log of the initial RNA concentration (pg) and the threshold cycle held true over a range of five orders of magnitude variation in the starting RNA concentration (for all experiments, the correlation coefficients were between 0.980-0.999). RT-PCR products from the serially-diluted standards and samples were analyzed by gel electrophoresis to confirm the presence of the specific amplicon (Fig. 3B).






Figure 3. LCM selectively enriches lesional macrophage RNA, as assessed by mRNA transcript levels of cell-specific markers. **A.** Representative standard curves from real-time quantitative RT-PCR of CD68 (□) and α -actin (○). The plot of cycle threshold versus log₁₀ of input starting concentration shows a linear relationship for 5 orders of magnitude of starting RNA. **B.** Electrophoretic analysis of the quantitative RT-PCR products. The semi-quantitative relationship (i.e., graded intensity of ethidium bromide stained bands) for the serial diluted standards (10 ng – 1pg; lanes 1-5) corresponds to that measured in **A.** **C.** The levels of macrophage specific CD68 were markedly increased in the LCM sample compared to the whole section RNA sample. **D.** There was no detectable amplification for smooth muscle cell-specific α -actin in the LCM foam cell derived RNA. The “*” indicates where the amplification of RNA from non specific cells would have been detected.

Table I. Sequences of Real-time quantitative RT-PCR primers and probes of measured gene transcripts.

| Gene/Primer | Sequence (5' → 3') | Position | Amplicon Length (bp) |
|--|-------------------------------|----------|----------------------|
| <i>Cyclophilin A (NM_008907)</i> | | | |
| Fwd | GGCCGATGACGAGCCC | 74-89 | 64 |
| Probe | TGGGCCGCTCTCCTTCGA | 91-109 | |
| Rev | TGCTTTGGAACCTTGTCTGCAA | 115-148 | |
| <i>CD68/Macrosialin (X68273)</i> | | | |
| Fwd | TTGGAACTACACAGTGGCC | 472-490 | 67 |
| Probe | CGGCTCCAGCCTTGTGTCAGC | 494-516 | |
| Rev | CGGATTTGAATTTGGGCTTG | 519-538 | |
| <i>α-actin (NM_007392)</i> | | | |
| Fwd | AACGCCTTCCGCTGCCC | 814-829 | 66 |
| Probe | AGACTCTCTCCAGCCATGTTTCATTGGGA | 832-861 | |
| Rev | CGATGCCGCTGACTCC | 863-879 | |
| <i>VCAM-1 (NM_011693)</i> | | | |
| Fwd | CCCCAAGGATCCAGAGATCA | 402-422 | 63 |
| Probe | TTCAGTGGCCCCCTGGAGTTG | 424-445 | |
| Rev | ACTTGACCGTGACCGGCTT | 448-466 | |
| <i>ICAM-1 (X52264)</i> | | | |
| Fwd | ATCTCAGGCCGCAAGGG | 600-616 | 66 |
| Probe | TGGCATTGTTCTAATGTTCTCCGAGGC | 617-645 | |
| Rev | CGAAAGTCCGAGGCTCC | 648-665 | |
| <i>MCP-1 (M19681)</i> | | | |
| Fwd | TTCTCCACCACCATGAG | 535-553 | 64 |
| Probe | CCCTGTGTCATGCTTCTGGGCTGC | 556-578 | |
| Rev | CCAGCCGGAACTGTGA | 582-598 | |

*The probes are labeled at the 5' and 3' positions with 6-carboxyfluorescein (FAM) reporter and a 6-carboxy-tetramethyl-rhodamine (TAMRA) quencher, respectively. The positions of the primers and probes are annotated according to the sequences derived from GenBank (accession numbers given in parenthesis).

Table II. Induction of pro-atherogenic mRNAs by LPS.

| mRNA transcript | Control | LPS | Ratio of Means (LPS : Control) |
|-----------------|---------------------|--------------------|--------------------------------|
| VCAM | 2.1 (1.6 - 2.1) | 22.1 (11.9 - 32.3) | 11.9 |
| ICAM | 0.3 (0.2 - 0.4) | 9.8 (4.1 - 15.4) | 32.5 |
| MCP-1 | 0.1 (0.126 - 0.128) | 3.9 (2.4 - 5.5) | 31.0 |

Real-time quantitative RT-PCR measurements (normalized to the control gene cyclophilin A) of RNA derived from LCM-isolated lesional macrophages from control and LPS-treated apolipoprotein E-/- animals are given as a mean (range).

REFERENCES

1. Smith, J.D., Trogan, E., Ginsberg, M., Grigaux, C., Tian, J., and Miyata, M. 1995. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. *Proc Natl Acad Sci USA*. 92:8264-8268.
2. Qiao, J.H., Tripathi, J., Mishra, N.K., Cai, Y., Tripathi, S., Wang, X.P., Imes, S., Fishbein, M.C., Clinton, S.K., Libby, P., Lusis, A.J., et al. 1997. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. *Am J Pathol*. 150:1687-1699.
3. de Villiers, W.J., Smith, J.D., Miyata, M., Dansky, H.M., Darley, E., and Gordon, S. 1998. Macrophage phenotype in mice deficient in both macrophage-colony-stimulating factor (op) and apolipoprotein E. *Arterioscler Thromb Vasc Biol*. 18:631-640.
4. Chong, P.H., and Bachenheimer, B.S. 2000. Current, new and future treatments in dyslipidaemia and atherosclerosis. *Drugs*. 60:55-93.
5. Brewer, H.B., Jr. 2000. The lipid-laden foam cell: an elusive target for therapeutic intervention. *J Clin Invest*. 105:703-705.
6. Plutzky, J. 1999. Atherosclerotic plaque rupture: emerging insights and opportunities. *Am J Cardiol*. 84:15J- 20J.
7. Emmert-Buck, M.R., Bonner, R.F., Smith, P.D., Chuaqui, R.F., Zhuang, Z., Goldstein, S.R., Weiss, R.A., and Liotta, L.A. 1996. Laser capture microdissection. *Science*. 274:998- 1001.
8. Bonner, R.F., Emmert-Buck, M., Cole, K., Pohida, T., Chuaqui, R., Goldstein, S., and Liotta, L.A. 1997. Laser capture microdissection: molecular analysis of tissue. *Science*. 278:1481,1483.
9. Ramprasad, M.P., Fischer, W., Witztum, J.L., Sambrano, G.R., Quehenberger, O., and Steinberg, D. 1995. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. *Proc Natl Acad Sci U S A*. 92:9580-9584.
10. Ramprasad, M.P., Terpstra, V., Kondratenko, N, Quehenberger, O., and Steinberg, D. 1996. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. *Proc Natl Acad Sci U S A*. 93:14833-14838.
11. Fend, F., Emmert-Buck, M.R., Chuaqui, R., Cole, K., Lee, J., Liotta, L.A., and Raffeld, M. 1999. Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. *Am J Pathol*. 154:61- 66.
12. Bustin, S.A. 2000. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol*. 25:169-193.



LAXCO, Inc.
18303 Bothell-Everett Hwy
Suite 140
Mill Creek, WA 98012
www.laxcoinc.com

Contact us:
425-686-3081
AccuvaCollect@laxcoinc.com

LMC-MKT-DOC-1700127